|
|
Since 1996, eleven states have legalized medical
marijuana use: AK, AZ, CA, CO, HI, ME, NV, OR, RI, VT and WA.
Eight of the ten did so through the initiative process,
Hawaii's law was enacted by the legislature and signed by
the governor in 2000, Vermont's was enacted by the
legislature and passed into law without the governor's
signature in May 2004, and Rhode Island's was enacted
overriding the governor's veto in January 2006.
Source:
National Organization for the Reform of Marijuana Laws (NORML),
from the web at
http://www.norml.org/index.cfm?Group_ID=3391, last
accessed Jan. 4, 2006, and the Marijuana Policy Project (MPP),
from the web at
http://www.mpp.org/RI_number_11.phpl, last accessed Jan.
4, 2006.
The Institute of Medicine's 1999 report on medical
marijuana stated, "The accumulated data indicate a potential
therapeutic value for cannabinoid drugs, particularly for
symptoms such as pain relief, control of nausea and
vomiting, and appetite stimulation."
Source: Janet E. Joy, Stanley J.
Watson, Jr., and John A Benson, Jr.,
"Marijuana and
Medicine: Assessing the Science Base," Division of
Neuroscience and Behavioral Research, Institute of Medicine
(Washington, DC: National Academy Press, 1999).
The Institute of Medicine's 1999 report on medical
marijuana examined the question whether the medical use of
marijuana would lead to an increase of marijuana use in the
general population and concluded that, "At this point there
are no convincing data to support this concern. The existing
data are consistent with the idea that this would not be a
problem if the medical use of marijuana were as closely
regulated as other medications with abuse potential." The
report also noted that, "this question is beyond the issues
normally considered for medical uses of drugs, and should
not be a factor in evaluating the therapeutic potential of
marijuana or cannabinoids."
Source: Janet E. Joy,
Stanley J. Watson, Jr., and John A Benson, Jr.,
"Marijuana and
Medicine: Assessing the Science Base," Division of
Neuroscience and Behavioral Research, Institute of Medicine
(Washington, DC: National Academy Press, 1999).
In the Institute of Medicine's report on medical
marijuana, the researchers examined the physiological risks
of using marijuana and cautioned, "Marijuana is not a
completely benign substance. It is a powerful drug with a
variety of effects. However, except for the harms associated
with smoking, the adverse effects of marijuana use are
within the range of effects tolerated for other
medications."
Source: Janet E. Joy,
Stanley J. Watson, Jr., and John A Benson, Jr.,
"Marijuana and
Medicine: Assessing the Science Base," Division of
Neuroscience and Behavioral Research, Institute of Medicine
(Washington, DC: National Academy Press, 1999).
The Institute of Medicine's 1999 report on medical
marijuana examined the question of whether marijuana could
diminish patients' immune system - an important question
when considering marijuana use by AIDS and cancer patients.
The report concluded that, "the short-term immunosuppressive
effects are not well established but, if they exist, are not
likely great enough to preclude a legitimate medical use."
Source: Janet E. Joy,
Stanley J. Watson, Jr., and John A Benson, Jr.,
"Marijuana and
Medicine: Assessing the Science Base," Division of
Neuroscience and Behavioral Research, Institute of Medicine
(Washington, DC: National Academy Press, 1999).
"Conclusions: Smoked and oral cannabinoids did not seem
to be unsafe in people with HIV infection with respect to
HIV RNA levels, CD4+ and CD8+ cell counts, or protease
inhibitor levels over a 21-day treatment."
Source: Abrams, Donald I., MD, et al., "Short-Term Effects
of Cannabinoids in Patients with HIV-1 Infection - A
Randomized, Placebo-Controlled Clinical Trial," Annals of
Internal Medicine, Aug. 19, 2003, Vol. 139, No. 4 (American
College of Physicians), p. 258.
"This study provides evidence that short-term use of
cannabinoids, either oral or smoked, does not substantially
elevate viral load in individuals with HIV infection who are
receiving stable antiretroviral regimens containing nelfi-
navir or indinavir. Upper confidence bounds for all
estimated effects of cannabinoids on HIV RNA level from all
analyses were no greater than an increase of 0.23 log10
copies/mL compared with placebo. Because this study was
randomized and analyses were controlled for all known
potential confounders, it is very unlikely that chance
imbalance on any known or unknown covariate masked a harmful
effect of cannabinoids. Study participants in all groups may
have been expected to benefit from the equivalent of
directly observed antiretroviral therapy, as well as
decreased stress and, for some, improved nutrition over the
25-day inpatient stay."
Source:
Abrams, Donald I., MD, et al., "Short-Term Effects of
Cannabinoids in Patients with HIV-1 Infection - A
Randomized, Placebo-Controlled Clinical Trial," Annals of
Internal Medicine, Aug. 19, 2003, Vol. 139, No. 4 (American
College of Physicians), p. 264.
"Nevertheless, when considering all 15 studies (i.e.,
those that met both strict and more relaxed criteria) we
only noted that regular cannabis users performed worse on
memory tests, but that the magnitude of the effect was very
small. The small magnitude of effect sizes from observations
of chronic users of cannabis suggests that cannabis
compounds, if found to have therapeutic value, should have a
good margin of safety from a neurocognitive standpoint under
the more limited conditions of exposure that would likely
obtain in a medical setting."
Source:
Grant, Igor, et al., "Non-Acute (Residual) Neurocognitive
Effects Of Cannabis Use: A Meta-Analytic Study," Journal of
the International Neuropsychological Society (Cambridge
University Press: July 2003), 9, pp. 687-8.
In spite of the established medical value of marijuana,
doctors are presently permitted to prescribe cocaine and
morphine - but not marijuana.
Source: The Controlled Substances
Act of 1970, 21 U.S.C. §§ 801 et seq.
Organizations that have endorsed medical access to
marijuana include: the Institute of Medicine, the American
Academy of Family Physicians; American Bar Association;
American Public Health Association; American Society of
Addiction Medicine; AIDS Action Council; British Medical
Association; California Academy of Family Physicians;
California Legislative Council for Older Americans;
California Medical Association; California Nurses
Association; California Pharmacists Association; California
Society of Addiction Medicine; California-Pacific Annual
Conference of the United Methodist Church; Colorado Nurses
Association; Consumer Reports Magazine; Kaiser Permanente;
Lymphoma Foundation of America; Multiple Sclerosis
California Action Network; National Association of Attorneys
General; National Association of People with AIDS; National
Nurses Society on Addictions; New Mexico Nurses Association;
New York State Nurses Association; New England Journal of
Medicine; and Virginia Nurses Association.
A few of the editorial boards that have endorsed medical
access to marijuana include: Boston Globe; Chicago Tribune;
Miami Herald; New York Times; Orange County Register; and
USA Today.
Many organizations have favorable positions (e.g.,
unimpeded research) on medical marijuana. These groups
include: The Institute of Medicine, The American Cancer
Society; American Medical Association; Australian
Commonwealth Department of Human Services and Health;
California Medical Association; Federation of American
Scientists; Florida Medical Association; and the National
Academy of Sciences.
The Controlled Substances Act of 1970 established five
categories, or "schedules," into which all illicit and
prescription drugs were placed. Marijuana was placed in
Schedule I, which defines the substance as having a high
potential for abuse, no currently accepted medical use in
the United States, and a lack of accepted safety for use
under medical supervision. To contrast, over 90 published
reports and studies have shown marijuana has medical
efficacy.
Source: The Controlled
Substances Act of 1970, 21 U.S.C. §§ 801 et seq.; Common
Sense for Drug Policy, Compendium of Reports, Research and
Articles Demonstrating the Effectiveness of Medical
Marijuana, Vol. I & Vol. II (Falls Church, VA: Common Sense
for Drug Policy, March 1997).
The U.S. Penal Code states that any person can be
imprisoned for up to one year for possession of one
marijuana cigarette and imprisoned for up to five years for
growing a single marijuana plant.
Source: The Controlled
Substances Act of 1970, 21 U.S.C. §§ 801 et seq.
On September 6, 1988, the Drug Enforcement
Administration's Chief Administrative Law Judge, Francis L.
Young, ruled:
"Marijuana, in its natural form, is one of the safest
therapeutically active substances known....[T]he provisions
of the [Controlled Substances] Act permit and require the
transfer of marijuana from Schedule I to Schedule II. It
would be unreasonable, arbitrary and capricious for the DEA
to continue to stand between those sufferers and the
benefits of this substance."
Source: US Department
of Justice, Drug Enforcement Agency, "In the Matter of
Marijuana Rescheduling Petition," [Docket #86-22] (September
6, 1988), p. 57.
The DEA's Administrative Law Judge, Francis Young
concluded: "In strict medical terms marijuana is far safer
than many foods we commonly consume. For example, eating 10
raw potatoes can result in a toxic response. By comparison,
it is physically impossible to eat enough marijuana to
induce death. Marijuana in its natural form is one of the
safest therapeutically active substances known to man. By
any measure of rational analysis marijuana can be safely
used within the supervised routine of medical care."
Source: US Department
of Justice, Drug Enforcement Agency, "In the Matter of
Marijuana Rescheduling Petition," [Docket #86-22],
(September 6, 1988), p. 57.
Between 1978 and 1997, 35 states and the District of
Columbia passed legislation recognizing marijuana's
medicinal value.
States include: AL, AZ, AR, CA, CO, CT, FL, GA, IL, IA, LA,
MA, ME, MI, MN, MO, MT, NV, NH, NJ, NM, NY, NC, OH, OK, OR,
RI, SC, TN, TX, VT, VA, WA, WV, and WI.
For additional
research on medical marijuana, see this excellent
analysis of medical
marijuana research by Common Sense for Drug Policy President
Kevin B. Zeese and this
update from
Common Sense for Drug Policy, as well as
the Drug War
Facts section on marijuana.
|
|
 |
 |
|
|